Ashley Gallagher

Enhanced education can reduce uncertainty among both patients and providers, with pharmacists playing a key role as primary sources of patient information.

Misinformation regarding the use of corticosteroids remains persistent and may have implications on patient care.

Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.

The paper was authored and issued by the FDA Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, and Office of Combination Products.

A combined treatment regimen of encorafenib and binimetinib led to improved progression-free survival, overall response rate, and tolerability in patients with advanced BRAF-mutant melanoma.